Evidence map›Paper›PMID 40749104›Full record

ArticleJournal of medicinal chemistry2025

Design and Development of Lysyl tRNA Synthetase Inhibitors, for the Treatment of Tuberculosis.

Susan H Davis, Michael Mathieson, Kirsteen I Buchanan, Alice Dawson, Alasdair Smith, Mattia Cocco, Fabio K Tamaki, John M Post, Beatriz Baragaña, Chimed Jansen and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Susan H DavisDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Michael MathiesonDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Kirsteen I BuchananDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Alice DawsonDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.ORCID 0000-0002-3284-553X
Alasdair SmithDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Mattia CoccoDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.ORCID 0000-0003-4358-8599
Fabio K TamakiDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.ORCID 0000-0003-2515-8202
John M PostDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Beatriz BaragañaDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.ORCID 0000-0002-0959-1113
Chimed JansenDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Michael KiczunDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Fabio ZuccottoDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Gavin WoodDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Paul ScullionDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Peter C RayDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Ola EpemoluDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Eva Maria Lopez-RománGlobal Health Medicines R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain.
Laura Guijarro LópezGlobal Health Medicines R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain.
Curtis A EngelhartDept. of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States.
Jia KimDept. of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States.
Paula A PinoDept. of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States.
Dirk SchnappingerDept. of Microbiology and Immunology, Weill Cornell Medical College, New York, New York 10065, United States.ORCID 0000-0002-4445-7219
Kevin D ReadDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.ORCID 0000-0002-8536-0130
Lourdes EncinasGlobal Health Medicines R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain.
Robert H BatesGlobal Health Medicines R&D, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760 Madrid, Spain.ORCID 0000-0003-1926-8114
Paul G WyattDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.
Simon R GreenDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.ORCID 0000-0001-5054-4792
Laura A T CleghornDrug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, DD1 5EH Dundee, U.K.ORCID 0000-0001-6218-0092

Funding

Gates Foundation INV-004709Gates Foundation INV-004761Gates Foundation INV-010616Wellcome Trust
6 · The paper itself

Abstract

There is currently a public health crisis due to the rise of multidrug-resistant tuberculosis cases, as well as the rise in the number of deaths from tuberculosis. To achieve the United Nations Sustainable Development Goal of ending the tuberculosis epidemic by 2030, new treatments are urgently required. We previously reported the discovery of

Indexed as

Antitubercular AgentsDrug DesignEnzyme InhibitorsLysine-tRNA LigaseMycobacterium tuberculosisTuberculosisAnimalsHumansMiceStructure-Activity RelationshipAntitubercular AgentsEnzyme InhibitorsLysine-tRNA Ligase

Identifiers

PMID40749104
PMCPMC12362622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.